<DOC>
	<DOCNO>NCT02822599</DOCNO>
	<brief_summary>The goal study determine whether use Human Fibrinogen Concentrate ( RiaSTAP ) decrease need component blood therapy neonates infant undergo cardiopulmonary bypass .</brief_summary>
	<brief_title>Human Fibrinogen Concentrate Pediatric Cardiac Surgery</brief_title>
	<detailed_description>The goal study determine whether use Human Fibrinogen Concentrate ( RiaSTAP ) decrease need component blood therapy neonates infant undergo cardiopulmonary bypass . RiaSTAP administer termination Cardiopulmonary Bypass ( CPB ) dose 70 mg/kg , prospective , randomize , control study . We hypothesize administration RiaSTAP manner reduce peri-operative bleeding transfusion requirement .</detailed_description>
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<mesh_term>Afibrinogenemia</mesh_term>
	<criteria>Neonatal infant cardiac patient present openheart surgery Nicklaus Children 's Hospital eligible enrollment study . Patients fall outside age range study exclude . Patients know anaphylactic severe reaction drug component enrol . At time rewarming ROTEM , patient FIBTEM MCF &gt; 15mm , exclude .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>1 Year</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>CBP , congenital heart defect , cardiopulmonary bypass</keyword>
</DOC>